Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Quick-Clot powder could save lives in severe trauma bleeding

NCT ID NCT05449834

Disease control Sponsor: Australian and New Zealand Intensive Care Research Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study compares two treatments to help blood clot in severely injured trauma patients who are bleeding heavily. One is a standard frozen blood product (cryoprecipitate) that takes time to thaw, and the other is a dry powder (fibrinogen concentrate) that can be given at the bedside. The goal is to see if the faster option helps patients spend more days alive and out of the hospital within 90 days. About 850 adults from Australia and New Zealand will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

900 people

The number who actually took part.

Started

Nov 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult affected by trauma (≥18yrs) 2. Judged to have active haemorrhage by treating clinician 3. Activation of local MHP and/or Transfusion of Emergency Blood Products 4. FIBTEM A5 ≤ 10mm or TEG FF A5 ≤ 15mm or FibC ≤ 2 g/l Exclusion Criteria: 1. Injury judged incompatible with survival 2. Randomisation unable to occur within 6 hours of presentation to hospital 3. Known pregnancy 4. Known genetic or drug induced coagulation disorder 5. Known objection to blood products 6. Dedicated prior fibrinogen replacement 7. Participation in a competing study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coagulopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

blood coagulation disease injury Shock, Hemorrhagic vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coagulopathy Haemorrhagic shock Trauma

Contacts and locations

Locations

  • Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • Aukland City Hospital

    Auckland, Aukland, 1023, New Zealand

  • Cairns Hospital

    Cairns, Queensland, 4870, Australia

  • Flinders Medical Centre

    Adelaide, South Australia, 5042, Australia

  • Gold Coast University Hospital

    Gold Coast, Queensland, 4215, Australia

  • John Hunter Hospital

    Newcastle, New South Wales, 2305, Australia

  • Liverpool Hospital

    Sydney, New South Wales, 2170, Australia

  • Middlemore Hospital

    Auckland, Aukland, 2025, New Zealand

  • Princess Alexandra Hospital

    Brisbane, Queensland, 4102, Australia

  • Rockhampton Hospital

    Rockhampton, Queensland, 4700, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, 4006, Australia

  • Royal Darwin Hospital

    Darwin, Northern Territory, 0810, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, 7000, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, 3050, Australia

  • Royal North Shore Hospital

    Sydney, New South Wales, 2065, Australia

  • Royal Perth Hospital

    Perth, Western Australia, 6000, Australia

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, 2050, Australia

  • St Vincent's Hospital

    Sydney, New South Wales, 2010, Australia

  • Sunshine Coast University Hospital

    Sunshine Coast, Queensland, 4575, Australia

  • Townsville Hospital

    Townsville, Queensland, 4814, Australia

  • Waikato Hospital

    Hamilton, Hamilton, 3204, New Zealand

  • Wellington Hospital

    Wellington, Wellington Region, 6021, New Zealand

  • Westmead Hospital

    Sydney, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.